Pharmaceutical intermediates
Lemborexant Intermediates
4 pharmaceutical intermediates for Lemborexant. Indication: Sleep Initiation and Maintenance Disorders.
About Lemborexant
- Originator
- Eisai Inc
- Indication
- Sleep Initiation and Maintenance Disorders
- Approved Date
- 04/07/2020
- NCE Patent
- 04/07/2025
- DS/DP
- 09/20/2031
Available intermediates
4 intermediates currently listed for Lemborexant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (1S,5R)-1-(3-fluorophenyl)-3-oxabicyclo[3.1.0]hexan-2-one | 528587-70-4 | / | / |
| ((1S,2R)-1-(3-fluorophenyl)cyclopropane-1,2-diyl)dimethanol | 1369767-20-3 | / | / |
| (1R,2S)-2-(3-fluorophenyl)-2-(hydroxymethyl)cyclopropyl]-methyl acetate | 1369768-29-5 | / | / |
| 5-Pyrimidinol, 2,4-dimethyl- (9CI) | 412003-95-3 | / | / |
Building toward Lemborexant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →